Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Inhibitory Checkpoint Molecule Clear all

Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011

View directory record Official record

Conditions: Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions: lorigerlimab, docetaxel, Prednisone; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more

Source: ClinicalTrials.gov public record

Updated Apr 16, 2026 · Synced May 21, 2026, 6:22 PM EDT

Terminated Phase 1 Interventional

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

NCT06188208

View directory record Official record

Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
Interventions: VVD-130850, Pembrolizumab; Drug
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 6 more

Source: ClinicalTrials.gov public record

Updated Mar 29, 2026 · Synced May 21, 2026, 6:22 PM EDT